YES1 (T348I)
Sign in to save this workspaceYES1 · Variant type: point · HGVS: p.T348I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 99.5% | 0.5% | 88.97 |
| 2 | Selpercatinib | 99.0% | 1.0% | 96.72 |
| 3 | Brigatinib | 98.3% | 1.7% | 82.96 |
| 4 | Futibatinib | 98.1% | 1.9% | 98.48 |
| 5 | Vandetanib | 97.2% | 2.8% | 95.74 |
| 6 | Crizotinib | 95.9% | 4.1% | 91.39 |
| 7 | Repotrectinib | 95.5% | 4.5% | 84.21 |
| 8 | Nintedanib | 95.2% | 4.8% | 90.23 |
| 9 | Pacritinib | 94.6% | 5.4% | 88.64 |
| 10 | Pralsetinib | 94.2% | 5.8% | 93.43 |
| 11 | Entrectinib | 93.5% | 6.5% | 93.69 |
| 12 | Ponatinib | 91.8% | 8.2% | 78.23 |
| 13 | Sunitinib | 83.9% | 16.1% | 91.73 |
| 14 | Axitinib | 83.1% | 16.9% | 93.23 |
| 15 | Fedratinib | 82.2% | 17.8% | 96.21 |
| 16 | Tivozanib | 77.6% | 22.4% | 92.42 |
| 17 | Bosutinib | 77.4% | 22.6% | 87.22 |
| 18 | Defactinib | 77.1% | 22.9% | 92.68 |
| 19 | Lorlatinib | 74.2% | 25.8% | 97.24 |
| 20 | Dacomitinib | 68.3% | 31.7% | 97.99 |
| 21 | Fostamatinib | 66.1% | 33.9% | 96.74 |
| 22 | Canertinib | 65.6% | 34.4% | 96.49 |
| 23 | Alpelisib | 63.5% | 36.5% | 97.22 |
| 24 | Erdafitinib | 62.9% | 37.1% | 95.71 |
| 25 | Avapritinib | 58.3% | 41.7% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 99.5% | — | — |
| Selpercatinib | 99.0% | — | — |
| Brigatinib | 98.3% | — | — |
| Futibatinib | 98.1% | — | — |
| Vandetanib | 97.2% | — | — |
| Crizotinib | 95.9% | — | — |
| Repotrectinib | 95.5% | — | — |
| Nintedanib | 95.2% | — | — |
| Pacritinib | 94.6% | — | — |
| Pralsetinib | 94.2% | — | — |
| Entrectinib | 93.5% | — | — |
| Ponatinib | 91.8% | — | — |
| Sunitinib | 83.9% | — | — |
| Axitinib | 83.1% | — | — |
| Fedratinib | 82.2% | — | — |
| Tivozanib | 77.6% | — | — |
| Bosutinib | 77.4% | — | — |
| Defactinib | 77.1% | — | — |
| Lorlatinib | 74.2% | — | — |
| Dacomitinib | 68.3% | — | — |
| Fostamatinib | 66.1% | — | — |
| Canertinib | 65.6% | — | — |
| Alpelisib | 63.5% | — | — |
| Erdafitinib | 62.9% | — | — |
| Avapritinib | 58.3% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| osteosarcoma_bone | Bone | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.2ms